Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.07 Insider Own0.20% Shs Outstand40.92M Perf Week-7.58%
Market Cap843.36M Forward P/E- EPS next Y-3.42 Insider Trans39.09% Shs Float37.67M Perf Month-5.07%
Income-113.00M PEG- EPS next Q-0.95 Inst Own66.30% Short Float30.61% Perf Quarter-32.71%
Sales15.50M P/S54.41 EPS this Y35.60% Inst Trans0.74% Short Ratio8.07 Perf Half Y-13.98%
Book/sh7.52 P/B2.74 EPS next Y4.50% ROA-37.40% Target Price38.07 Perf Year-57.04%
Cash/sh6.83 P/C3.02 EPS next 5Y9.31% ROE-44.20% 52W Range12.12 - 55.61 Perf YTD1.18%
Dividend- P/FCF- EPS past 5Y-9.80% ROI-36.30% 52W High-62.94% Beta0.58
Dividend %- Quick Ratio10.40 Sales past 5Y-7.80% Gross Margin- 52W Low70.05% ATR1.09
Employees146 Current Ratio10.40 Sales Q/Q-13.30% Oper. Margin- RSI (14)40.02 Volatility5.52% 5.20%
OptionableYes Debt/Eq0.01 EPS Q/Q-41.70% Profit Margin- Rel Volume0.67 Prev Close20.79
ShortableYes LT Debt/Eq0.01 EarningsAug 07 BMO Payout- Avg Volume1.43M Price20.61
Recom2.40 SMA20-9.29% SMA50-6.41% SMA200-20.86% Volume963,572 Change-0.87%
01-Aug-14Initiated Oppenheimer Outperform $45
29-Jul-14Upgrade WBB Securities Speculative Buy → Buy $25
22-Apr-14Reiterated Needham Buy $36 → $52
22-Apr-14Reiterated Deutsche Bank Hold $17 → $35
04-Mar-14Reiterated Canaccord Genuity Hold $25 → $27
21-Jan-14Upgrade Needham Hold → Buy $36
26-Nov-13Upgrade WBB Securities Sell → Speculative Buy $9 → $19
13-Nov-13Downgrade Needham Buy → Hold
13-Nov-13Downgrade Deutsche Bank Buy → Hold $71 → $17
12-Nov-13Reiterated FBR Capital Mkt Perform $48 → $20
30-Oct-13Initiated FBR Capital Mkt Perform $48
06-Sep-13Initiated Stifel Buy $51
22-Apr-13Initiated Needham Buy $57
04-Apr-13Initiated Robert W. Baird Outperform $63
03-Apr-13Initiated Robert W. Baird Outperform $63
08-Mar-13Reiterated Burrill Institutional Research Mkt Outperform $54 → $39
26-Nov-12Initiated Burrill Institutional Research Mkt Outperform $54
12-Sep-12Downgrade WBB Securities Hold → Sell $8 → $9
09-Aug-12Initiated WBB Securities Hold $8
09-Aug-12Downgrade WBB Securities Speculative Buy → Hold
23-Sep-14 05:47PM  Race to treat ebola CNBC
09:16AM  Ebola drugs to be fast-tracked in W. Africa; Ascena Retail shares tumble; Philips to split Hot Stock Minute
08:03AM  Investors watch Syria; Lew rewrites inversion rules; Apple's Beats go on? Hot Stock Minute
06:29AM  Ebola drug trials to be fast-tracked in West Africa Reuters
11-Sep-14 02:20PM  Ebola-Stricken Doc Receives Experimental Drug, But Which One? at TheStreet
10:07AM  Ebola-Stricken Doc Receives Experimental Drug, But Which One? at TheStreet
10-Sep-14 09:36AM  Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity at TheStreet +5.14%
05-Sep-14 03:01PM  WHO Ebola Drug Panel: Use Survivor Serum To Treat Ebola Victims at Forbes
29-Aug-14 08:52AM  BioCryst to Launch NHP Ebola Drug Safety, Efficacy Studies 'Within Weeks' at Forbes
08:52AM  BioCryst to Launch NHP Ebola Drug Safety Studies 'Within Weeks' at Forbes
28-Aug-14 08:00AM  Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Business Wire
26-Aug-14 02:22PM  The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks at TheStreet
01:04PM  SAREPTA THERAPEUTICS, INC. Financials EDGAR Online Financials
12:38PM  How Will We Know If The Ebola Drugs Worked? at Forbes
21-Aug-14 09:00AM  Sarepta Enters into Partnership with Flagship Biosciences to Digitally Automate the Measurement of Dystrophin, a Key Therapeutic Efficacy Marker for Muscular Dystrophy Business Wire
19-Aug-14 12:40PM  [$$] Cash In on Taser's Gains With Moves in Options at Barrons.com
18-Aug-14 09:09AM  As Ebola Outbreak Expands, These Experimental Drugs Could See Action at Forbes
15-Aug-14 01:04PM  SAREPTA THERAPEUTICS, INC. Financials EDGAR Online Financials
12-Aug-14 02:35PM  Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss Zacks -5.74%
11-Aug-14 05:36PM  US STOCKS-Wall St ends up for second day on hopes for Russia relief Reuters +7.39%
05:30PM  [video] Biotechs race for Ebola cure at CNBC
03:29PM  Biotechs That Might Benefit From Ebola Benzinga
03:29PM  Biotechs That Might Benefit From Ebola Research Benzinga
08-Aug-14 02:04PM  Tekmira Ebola Drug Hold Lifted By FDA, Stock Soars at Investor's Business Daily +6.03%
11:09AM  Today's Dead Cat Bounce Stock Is Sarepta Therapeutics (SRPT) at TheStreet
07-Aug-14 08:52PM  FDA Moves On Tekmira's Ebola Drug While Sarepta's Sits Unused at Forbes -8.84%
03:19PM  [video] Ebola not easily spread: Doctor at CNBC
02:17PM  [video] Pharma companies rush to help Ebola at CNBC
02:04PM  Looking to trade on Ebola? Beware at CNBC
08:00AM  Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today CCBN
07:49AM  Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today CCBN
07:38AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an EDGAR Online
07:32AM  Sarepta Therapeutics Announces Second Quarter 2014 Financial Results and Recent Corporate Developments Business Wire
07:07AM  Q2 2014 Sarepta Therapeutics Inc. Earnings Release - Before Market Open CCBN
06:49AM  SAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
06-Aug-14 12:07PM  Sarepta Should Shut Up About Ebola, Focus on Job No. 1 at TheStreet
08:12AM  Ebola: Why there isn't a vaccine, treatment, or cure Yahoo Finance
05-Aug-14 05:40PM  [video] Biotech firm targets Ebola at CNBC
07:33AM  Saving kids: When unapproved drugs are the only hope at CNBC
04-Aug-14 07:05PM  Sarepta Ready to Provide Ebola Drug if Needed at Barrons.com
06:36PM  [$$] Sarepta Ready to Provide Ebola Drug if Needed at Barrons.com
01-Aug-14 07:40AM  Coverage initiated on Sarepta Therapeutics by Oppenheimer Briefing.com
05:49AM  CEO Reasserts Control Over Biotech Developer of Muscular Dystrophy Drug at BusinessWeek
31-Jul-14 05:18PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online -6.93%
05:10PM  Sarepta Therapeutics Announces Appointment of John Hodgman As Interim Chairman Business Wire
11:15AM  Sarepta Therapeutics to Present Company Overview at Canaccord Annual Growth Conference Business Wire
10:54AM  Sarepta Therapeutics to Announce Second Quarter 2014 Financial Results and Corporate Update on August 7, 2014 Business Wire
06:54AM  Sarepta Therapeutics (SRPT) Soars: Stock Rises 12.8% Zacks
30-Jul-14 11:33AM  Sarepta Up 12% As FDA Is 'Actively Engaged' On Drug Application Benzinga +12.79%
11:22AM  Here's Why Aegerion and Sarepta Trade Higher Wednesday at TheStreet
29-Jul-14 03:46PM  Do We Have Any Drugs To Treat Ebola? at Forbes
03:16PM  [$$] Sarepta CEO Sheds Some Sway Over Management at The Wall Street Journal
09:06AM  Sarepta Therapeutics upgraded by WBB Securities Briefing.com
28-Jul-14 08:00AM  Stop Squabbling, Mom Tells Troubled Biotech: 'Just Get My Kid the Drug' at BusinessWeek
08:00AM  Mom Tells Troubled Biotech to Stop Squabbling: 'Just Get My Kid the Drug' at BusinessWeek
25-Jul-14 08:18AM  [$$] Chief Scientist Out at Sarepta Therapeutics at The Wall Street Journal
07:48AM  [$$] Chief Scientist Out at Sarepta Therapeutics at The Wall Street Journal
06:58AM  [$$] Chief Scientist Out at Sarepta Therapeutics at The Wall Street Journal
12:02AM  [$$] Chief Scientist Out at Sarepta Therapeutics at The Wall Street Journal
24-Jul-14 11:03PM  [$$] Chief Scientist Out at Sarepta Therapeutics at The Wall Street Journal
09:08PM  [$$] Chief Scientist Out at Sarepta Therapeutics at The Wall Street Journal
07:25PM  [$$] Chief Scientist Is Out at Biotech at The Wall Street Journal
09:37AM  Sarepta fired CSO not involved in eteplirsen, The Street reports theflyonthewall.com
09:21AM  The Story Behind Sarepta's Firing of its Top Scientist at TheStreet
06:52AM  Sarepta terminates Chief Scientific Officer Arthur Krieg at theflyonthewall.com
06:31AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
23-Jul-14 04:38PM  [video] PTC Therapeutics CFO: Positive News on Translarna Just the Start at TheStreet
09:01AM  Edelman's Perceptive Advisors Buying Amicus Therapeutics Ahead Of Phase III Data Release at Seeking Alpha
19-Jul-14 09:12AM  Roundtable: 3 Stocks Janet Yellen Is Dead Wrong About at Motley Fool
17-Jul-14 06:10PM  Your first trade for Friday at CNBC
05:59PM  [video] Fast Money Final Trade: GOOGL, MSFT & more at CNBC
08:12AM  The Zacks Analyst Blog Highlights: AbbVie, Shire, Gilead Sciences, Sarepta Therapeutics and Celgene Zacks
12-Jul-14 06:01PM  3 Stocks Crushed by the Market This Week at Motley Fool
11-Jul-14 04:33PM  3 Reasons Not to Worry About Sarepta Therapeutics Inc. at Motley Fool
04:00PM  Sarepta Plunges on Eteplirsen Study Results Zacks
09:49AM  Today's Dead Cat Bounce Stock Is Sarepta Therapeutics (SRPT) at TheStreet
08:50AM  Today's Top Biotech Stocks to Watch: Johnson & Johnson and Sarepta Therapeutics at Motley Fool
07:03AM  Sarepta Therapeutics Slumps: SRPT Tanks 12.9% in Session Zacks
10-Jul-14 05:45PM  [video] Stock Pops & Drops: COH, SRPT, CRAY, LB at CNBC -12.94%
04:26PM  Should Sarepta's Shares Be Tumbling? at Motley Fool
03:24PM  Deutsche Bank Questions Long-Term Efficacy Of Sarepta's Eteplirsen Following Trial News Benzinga
02:10PM  Why Sarepta Therapeutics Inc. Stock Collapsed at Motley Fool
01:39PM  Investors Remain Confident in Sarepta After Shares Fall 20 Percent StockTwits
01:28PM  Sarepta price target lowered to $34 from $52 at Roth Capital theflyonthewall.com
12:38PM  Sarepta potential for near-term approval lower after update, says Piper Jaffray theflyonthewall.com
11:52AM  Janney Capital reiterates Sell rating on Sarepta at theflyonthewall.com
11:50AM  Sarepta story correction issued by Wall Street Journal at theflyonthewall.com
11:38AM  Down 17%: Is Sarepta a Bad News Buy? at Motley Fool
10:54AM  Sarepta shares defended at Needham at theflyonthewall.com
10:51AM  Why Sarepta Therapeutics (SRPT) Stock Is Plunging Today at TheStreet
10:09AM  Sarepta shares fall on muscular dystrophy drug data at CNBC
08:47AM  Sarepta Releases New Data, Facing A Sea Change At Regulators at Forbes
08:47AM  Sarepta Data Disappoints Wall Street As Expert Sees A Sea Change At FDA at Forbes
08:47AM  Sarepta Data Disappoints As Expert Sees A Sea Change At FDA at Forbes
08:32AM  Sarepta says on track to initiate several new studies of eteplirsen at theflyonthewall.com
08:31AM  Latest Sarepta Study Update Shows Greater Decline in Walking Ability at TheStreet
08:31AM  [video] Sarepta to file for approval of Eteplirsen at CNBC
08:30AM  Sarepta Therapeutics Reports Long-Term Outcomes Through 144 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy Business Wire
08-Jul-14 01:06PM  [video] Rough day for biotech at CNBC -7.29%
07:06AM  Sarepta Therapeutics (SRPT) Enters Oversold Territory Zacks
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.